No new efficacy data accompanied the announcement. Prior signals for the components remain preliminary: muzastotug has shown encouraging responses and durability in a Phase 1b/2 MSS colorectal cancer cohort when paired with pembrolizumab, and INCA33890 monotherapy has produced early activity in checkpoint-sensitive and -insensitive tumors, including MSS CRC with and without liver metastases.
The news: Adagene and Incyte will launch a Phase 1 study in 2026 testing the combination of muzastotug, a masked anti-CTLA-4 antibody, with INCA33890, a TGFβR2 × PD-1 bispecific, in third-line MSS colorectal cancer patients both with and without liver metastases. Incyte will sponsor and run the trial; Adagene will supply muzastotug. The study will follow a dose-escalation safety run-in before moving to an efficacy expansion in chemotherapy-refractory patients. In parallel, Incyte has already advanced INCA33890 upstream into first line via a 700-patient Phase 3 study adding the agent to bevacizumab plus FOLFOX in MSS CRC, underscoring a franchise-level push around the bispecific.
Strategically, this is an expansion play for both companies built around tackling one of the hardest immuno-oncology settings. For Incyte, layering a CTLA-4 mechanism onto its PD-1 × TGFβR2 backbone broadens optionality if the bispecific alone does not convert immunologically cold tumors. It also creates read-across between third-line biology and the ongoing first-line registrational program, potentially sharpening patient selection hypotheses around TGFβ signaling, immune exclusion, and the particularly resistant liver metastasis subset. For Adagene, having the larger partner sponsor the study reduces cash burden and operational risk while positioning muzastotug as a plug-in backbone for PD-1–based bispecifics. The SAFEbody masking approach is central to that pitch: if it meaningfully widens the therapeutic index for CTLA-4, the company can credibly chase more immunomodulatory intensity without prohibitive toxicity.
For sites and CROs, the operational profile will be complex. Managing overlapping immune-related toxicities from CTLA-4 and PD-1, alongside unknowns from TGFβ pathway modulation, will require tight safety monitoring, hepatic function vigilance, and clear steroid-sparing algorithms—especially critical in patients with liver metastases, where immune hepatitis risk and baseline dysfunction can confound attribution. Enrollment may benefit from the large pool of refractory MSS CRC patients, but competition for this population remains high, and the trial’s stratification by liver metastasis status and emphasis on serial biopsies and translational sampling could raise site burden. Vendors with robust pharmacodynamic and biomarker capabilities around TGFβ signatures, Treg depletion, and intratumoral immune remodeling are likely to be prioritized. Regulators will look for clean dose-escalation data, evidence of manageable hepatic safety, and consistent signals within the liver metastasis subgroup, given historical resistance of that phenotype to checkpoint therapy.
The key watch items are timing, tolerability, and translational clarity. A 2026 start pushes any decision-enabling readout toward the late decade, heightening execution risk and potential overlap with readouts from Incyte’s first-line Phase 3. Early dose-escalation results will need to show that the combination can achieve biologically relevant exposure without CTLA-4–driven toxicity eroding feasibility. Any early response or durable disease control in the liver metastasis cohort would be strategically differentiating. Conversely, the field’s history—most notably prior disappointments with TGFβ-targeted combinations and limited gains from PD-1/CTLA-4 in MSS CRC—sets a high bar. Expect the sponsors to lean heavily on biomarker-defined narratives to guide next steps, including whether to advance to a randomized expansion against physician’s choice. If the signal is credible and tolerability holds, the path could converge with Incyte’s registrational plans; if not, this remains a targeted option value exercise rather than a pivot point for the MSS CRC landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
